The role of osteopontin in breast cancer: Clinical and experimental studies

Journal of Mammary Gland Biology and Neoplasia

Volumn 6, Issue 4, 2001, Pages 419-429

  Tuck, Alan B ^a,b,c   Chambers, Ann F ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Breast cancer; Clinical studies; Experimental studies; Malignancy; Osteopontin; Prognostic factor

Indexed keywords

ALPHAVBETA1 INTEGRIN; ALPHAVBETA5 INTEGRIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; HERMES ANTIGEN; INTEGRIN; OSTEOPONTIN; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; UROKINASE; VITRONECTIN RECEPTOR; SIALOGLYCOPROTEIN; SPP1 PROTEIN, HUMAN;

BREAST CANCER; BREAST CARCINOGENESIS; BREAST DEVELOPMENT; BREAST EPITHELIUM; CANCER CELL CULTURE; CANCER INVASION; CANCER SURVIVAL; CANCER THERAPY; CELL MIGRATION; HUMAN; LACTATION; METASTASIS; METASTASIS POTENTIAL; NONHUMAN; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; TISSUE DIFFERENTIATION; TREATMENT OUTCOME; ANIMAL; BREAST; BREAST TUMOR; DISEASE COURSE; FEMALE; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PHYSIOLOGY;

ANIMALS; BREAST; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; OSTEOPONTIN; SIALOGLYCOPROTEINS;

EID: 0035495596     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1014734930781     Document Type: Review

References (91)

1. D. R. Senger, C. A. Perruzzi, and A. Papadopoulos (1989). Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res. 9: 291-1299.
2. A. Franzen and D. Heinegard (1985). Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem. J. 232:715-724.
3. R. Patarca, R. A. Saavedra, and H. Cantor (1993). Molecular and cellular basis of genetic resistance to bacterial infection: The role of the early T-lymphocyte activation-1/osteopontin gene. Crit. Rev. Immunol. 13:225-246.
4. A. M. Craig, M. Nemir, B. B. Mukherjee, A. F. Chambers, and D. T. Denhardt (1988). Identification of the major phosphoprotein secreted by many rodent cell lines as 2ar/osteopontin: Enhanced expression in H- ras-transformed 3T3 cells. Biochem. Biophys. Res. Comm. 157:166-173.
5. C. W. Prince (1989). Secondary structure predictions for rat osteopontin. Connect. Tissue Res. 21:15-20.
6. J. Sodek, B. Ganss, and M. D. McKee (2000). Osteopontin. Crit. Rev. Oral Biol. Med. 11:279-303.
7. R. Agnihotri, H. C. Crawford, H. Haro, L. M. Matrisian, M. C. Havrda, and L. Liaw (2001). Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J. Biol. Chem. 276:28261-28267.
8. A. J. Oates, R. Barraclough, and P. S. Rudland (1997). The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis 17:1-15.
9. C. M. Giachelli and S. Steitz (2000). Osteopontin: A versatile regulator of inflammation and biomineralization. Matrix Biol. 19:615-622.
10. D. T. Denhardt, M. Noda, A. W. O'Regan, D. Pavlin, and J. S. Berman (2001). Osteopontin as a means to cope with environmental insults: Regulation of inflammation, tissue remodeling, and cell survival. J. Clin. Invest. 107:1055-1061.
11. D. S. Bautista, J. W. Xuan, C. Hota, A. F. Chambers, and J. F. Harris (1994). Inhibition of Arg-Gly-Asp(RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J. Biol. Chem. 269:23280-23285.
12. V. L. Morris, A. B. Tuck, S. M. Wilson, D. Percy, and A. F. Chambers (1993). Tumor progression and metastasis in murine D2 hyperplastic alveolar nodule mammary tumor cell lines. Cin. Exp. Metastasis 11:103-112.
13. A. B. Tuck, D. M. Arsenault, F. P. O'Malley, C. Hota, M. C. Ling, S. M. Wilson, and A. F. Chambers (1999). Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 18:4237-4246.
14. V. Sung, C. Gilles, A. Murray, R. Clarke, A. D. Aaron, N. Azumi, and E. W. Thompson (1998). The LCC15-MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype. Exp. Cell Res. 241:273-284.
15. J. A. Sharp, V. Sung, J. Slavin, E. W. Thompson, and M. A. Henderson (1999). Tumor cells are the source of osteopontin and bone sialoprotein expression in human breast cancer. Lab. Invest. 79:869-877.
16. A. J. Oates, R. Barraclough, and P. S. Rudland (1996). The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 13:97-104.
17. H. Chen, Y. Ke, A. J. Oates, R. Barraclough, and P. S. Rudland (1997). Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line. Oncogene 14:1581-1588.
18. V. Band, D. Zajchowski, K. Swisshelm, D. Trask, V. Kulesa, C. Cohen, J. Connolly, and R. Sager (1990). Tumor progression in four mammary epithelial cell lines derived from the same patient. Cancer Res. 50:7351-7357.
19. J. E. Price, A. Polyzos, R. D. Zhang, and L. M. Daniels (1990). Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res. 50:717-721.
20. V. Shanmugam, I. Chackalaparampil, G. C. Kundu, A. B. Mukherjee, and B. B. Mukherjee (1997). Altered sialylation of osteopontin prevents its receptor-mediated binding on the surface of oncogenically transformed tsB77 cells. Biochemistry 36:5729-5738.
21. E. S. Sorensen, P. Hojrup, and T. E. Petersen (1995). Posttranslational modifications of bovine osteopontin: Identification of twenty-eight phosphorylation and three O-glycosylation sites. Protein Sci. 4: 040-2049.
22. R. A. Saavedra, S. K. Kimbro, D. N. Stern, J. Schnuer, S. Ashkar, M. J. Glimcher, and C. I. Ljubetic (1995). Gene expression and phosphorylation of mouse osteopontin. Ann. N. Y. Acad. Sci. 760: 5-43.
23. E. Salih, H. Y. Zhou, and M. J. Glimcher (1996). Phosphorylation of purified bone sialoprotein and osteopontin by protein kinases. J. Biol. Chem. 271:16897-16905.
24. S. Jono, C. Peinado, and C. M. Giachelli (2000). Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle calcification. J. Biol. Chem. 275:20197-20203.
25. C. W. Prince, D. Dickie, and C. L. Krumdieck (1991). Osteopontin, a substrate for transglutaminase and factor XIII activity. Biochem. Biophys. Res. Commun. 177:1205-1210.
26. E. S. Sorensen and T. E. Petersen (1995). Phosphorylation, glycosylation, and transglutaminase sites in bovine osteopontin. Ann. N. Y. Acad. Sci. 760:363-366.
27. M. T. Kaartinen, A. Pirhonen, A. Linnala-Kankkunen, and P. H. Maenpaa (1999). Cross-linking of osteopontin by tissue transglutaminase increases collagen binding properties. J. Biol. Chem. 274:1729-1735.
28. D. R. Senger, C. A. Perruzzi, A. Papadopoulos-Sergiou, and L. Van de Water (1994). Adhesive properties of osteopontin: Regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Mol. Biol. Cell 5:565-574.
29. D. R. Senger and C. A. Perruzzi (1996). Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin. Biochim. Biophys. Acta 1314:13-24.
30. S. T. Barry, S. B. Ludbrook, E. Murrison, and C. M. Horgan (2000). A regulated interaction between alpha5beta1 integrin and osteopontin. Biochem. Biophys. Res. Commun. 267:764-769.
31. O. Helluin, C. Chan, G. Vilaire, S. Mousa, W. F. DeGrado, and J. S. Bennett (2000). The activation state of alphav-beta3 regulates platelet and lymphocyte adhesion to intact and thrombin-cleaved osteopontin. J. Biol. Chem. 275:18337-18343.
32. Y. Yokasaki and D. Sheppard (2000). Mapping of the cryptic integrin-binding site in osteopontin suggests a new mechanism by which thrombin can regulate inflammation and tissue repair. Trends Cardiovasc. Med. 10:155-159.
33. S. R. Rittling and K. E. Novick (1997). Osteopontin expression in mammary gland development and tumorigenesis. Cell Growth Differ. 8: 061-1069.
34. M. G. Baik, M. J. Lee, and Y. J. Choi (1998). Gene expression during involution of mammary gland (review). Int. J. Mol. Med. 2: 9-44.
35. M. Nemir, D. Bhattacharyya, X. Li, K. Singh, A. B. Mukherjee, and B. B. Mukherjee (2000). Targeted inhibition of osteopontin expression in the mammary gland causes abnormal morphogenesis and lactation deficiency. J. Biol. Chem. 275:969-976.
36. L. F. Brown, B. Berse, L. Van de Water, A. Papadopoulos-Sergiou, C. A. Perruzzi, E. J. Manseau, H. F. Dvorak, and D. R. Senger (1992). Expression and distribution of osteopontin in human tissues: Widespread association with luminal epithelial surfaces. Mol. Biol. Cell 3: 169-1180.
37. D. R. Senger, C. A. Perruzzi, A. Papadopoulos, and D. G. Tenen (1989). Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin. Biochim. Biophys. Acta 996: 3-48.
38. J. W. Xuan, C. Hota, and A. F. Chambers (1994). Recombinant GST-human osteopontin fusion protein is functional in RGD-dependent cell adhesion. J. Cell. Biochem. 54:247-255.
39. J. W. Xuan, C. Hota, Y. Shigeyama, J. A. D'Errico, M. J. Somerman, and A. F. Chambers (1995). Site-directed mutagenesis of the argenine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions. J. Cell. Biochem. 57: 80-690.
40. A. B. Tuck, B. E. Elliott, C. Hota, E. Tremblay, and A. F. Chambers (2000). Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J. Cell. Biochem. 78:465-475.
41. N. C. Wong, B. M. Mueller, C. F. Barbas, P. Ruminski, V. Quaranta, E. C. Lin, and J. W. Smith (1998). Alphav integrins mediate adhesion and migration of breast carcinoma cell lines. Clin. Exp. Metastasis 16:50-61.
42. L. L. Smith, H. K. Cheung, L. E. Ling, J. Chen, D. Shepard, R. Pytola, and C. M. Giachelli (1996). Osteopontin N-terminal domain contacts a cryptic adhesive sequence recognized by α9β1 integrin. J. Biol. Chem. 271:28485-28491.
43. S. Denda, L. F. Reichardt, and U. Müller (1998). Identification of osteopontin as a novel ligand for the integrin α8β1 and potential roles for this integrin ligand interaction in kidney morphogenesis. Mol. Biol. Cell 9:1425-1435.
44. K. A. Bayless, G. A. Meininger, J. M. Scholtz, and G. E. Davis (1998). Osteopontin is a ligand for the α4β1 integrin. J. Cell Sci. 111:1165-1174.
45. H. Joensuu, P. J. Klemi, S. Toikkanen, and S. Jalkanen (1993). Glycoprotein CD44 expression and its association with survival in breast cancer. Am. J. Pathol. 143:867-874.
46. K. Friedrichs, F. Franke, B. W. Lisboa, G. Kugler, I. Gille, H. J. Terpe, F. Holzel, H. Maass, and U. Gunthert (1995). CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res. 55:5424-5433.
47. M. Kaufmann, K. H. Heider, H. P. Sinn, G. von Minckwitz, H. Ponta, and P. Herrlich (1995). CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 345: 615-619.
48. A. Bankfalvi, H. J. Terpe, D. Breukelmann, B. Bier, D. Rempe, G. Pschadka, R. Krech, and W. Bocker (1998). Gains and losses of CD44 expression during breast carcinogenesis and tumour progression. Histopathology 33:107-116.
49. G. F. Weber, S. Ashkar, M. J. Glimcher, and H. Cantor (1996). Receptor-ligand interaction between CD44 and osteopontin (ETA-1). Science 271:509-512.
50. A. Herrera-Gayol and S. Jothy (1999). Adhesion proteins in the biology of breast cancer: Contribution of CD44. Exp. Mol. Pathol. 66: 49-156.
51. J. A. Foekens, P. Dall, J. G. Klijn, P. Skroch-Angel, C. J. Claassen, M. P. Look, H. Ponta, W. L. Van Putten, P. Herrlich, and S. C. Henzen-Logmans (1999). Prognostic value of CD44 variant expression in primary breast cancer. Int. J. Cancer 84:209-215.
52. G. F. Weber, S. Ashkar, and H. Cantor (1997). Interaction between CD44 and osteopontin as a potential basis for metastasis formation. Proc. Assoc. Am. Physicians 109:1-9.
53. Y. U. Katagiri, J. Sleeman, H. Fujii, P. Herrlich, H. Hotta, K. Tanaka, S. Chikuma, H. Yagita, K. Okumura, M. Murakami, I. Saiki, A. F. Chambers, and T. Uede (1999). CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res. 59:219-226.
54. A. Herrera-Gayol and S. Jothy (1999). CD44 modulates Hs578T human breast cancer cell adhesion, migration, and invasiveness. Exp. Mol. Pathol. 66:99-108.
55. N. Harada, T. Mizoi, M. Kinouchi, K. Hoshi, S. Ishii, K. Shiiba, I. Sasaki, and S. Matsuno (2001). Introduction of antisense CD44s cDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells. Int. J. Cancer 91:67-75.
56. L. Y. Bourguignon, Z. Gunja-Smith, N. Iida, H. B. Zhu, L. J. Young, W. J. Muller, and R. D. Cardiff (1998). CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J. Cell. Physiol. 176:206-215.
57. A. B. Tuck, B. E. Elliott, C. Hota, and A. F. Chambers (2001). Osteopontin-induced migration of human mammary epithelial cells involves at least two growth factor/receptor pathways and multiple different signal transduction pathways. Proc. Am. Assoc. Cancer Res. 42. (Abstract No. 775).
58. L. Liaw, M. P. Skinner, E. W. Raines, R. Ross, D. A. Cheresh, S. M. Schwartz, and C. M. Giachelli (1995). The adhesive and migratory functions of osteopontin are mediated via distinct cell surface integrins. Role of alphav beta3 in smooth muscle cell migration to osteopontin in vitro. J. Clin. Invest. 95:713-724.
59. I. Carey, C. L. Williams, D. K. Ways, and J. D. Noti (1999). Overexpression of protein kinase C-alpha in MCF-7 breast cancer cells results in differential regulation and expression of alphav-beta3 and alphavbeta5. Int. J. Oncol. 15:127-136.
60. J. D. Noti (2000). Adherence to osteopontin via alphavbeta3 suppresses phorbol ester-mediated apoptosis in MCF-7 breast cancer cells that overexpress protein kinase C-alpha. Int. J. Oncol. 17: 237-1243.
61. A. B. Tuck, C. Hota, and A. F. Chambers (2001). Osteopontin (OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Res. Treat. 70:197-204.
62. P. A. Andreasen, L. Kjoller, L. Christensen, and M. J. Duffy (1997). The urokinase-type plasminogen activator system in cancer metastasis: A review. Int. J. Cancer 72:1-22.
63. J. L. Fisher, C. L. Field, H. Zhou, T. L. Harris, M. A. Henderson, and P. F. Choong (2000). Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases - a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Breast Cancer Res. Treat. 61: -12.
64. P. C. Brooks, S. Stromblad, L. C. Sanders, T. L. von Schalscha, R. T. Aimes, W. G. Stetler-Stevenson, J. P. Quigley, and D. A. Cheresh (1996). Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alphavbeta3. Cell 85:683-693.
65. P. Koistinen, T. Pulli, V. J. Uitto, L. Nissinen, T. Hyypia, and J. Heino (1999). Depletion of alphav integrins from osteosarcoma cells by intracellular antibody expression induces bone differentiation marker genes and suppresses gelatinase (MMP-2) synthesis. Matrix Biol. 18:239-251.
66. A. Teti, A. R. Farina, I. Villanova, A. Tiberio, A. Tacconelli, G. Sciotino, A. F. Chambers, A. Gulino, and A. R. Mackay (1998). Activation of MMP-2 by human GCT23 giant cell tumour cells induced by osteopontin, bone sialoprotein and GRGDSP peptide is RGD and cell shape change dependent. Int. J. Cancer 77:82-93.
67. E. I. Deryugina, M. A. Bourdon, K. Jungwirth, J. W. Smith, and A. Y. Strongin (2000). Functional activation of integrin alphavbeta3 in tumor cells expressing membrane-type 1 matrix metalloproteinase. Int. J. Cancer 86:15-23.
68. M. Yebra, G. C. Parry, S. Stromblad, N. Mackman, S. Rosenberg, B. M. Mueller, and D. A. Cheresh (1996). Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. J. Biol. Chem. 271:29393-29399.
69. M. V. Carriero, S. Del Vecchio, M. Capozzoli, P. Franco, L. Fontana, A. Zannetti, G. Botti, G. D'Aiuto, M. Salvatore, and M. P. Stoppelli (1999). Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res. 59:5307-5314.
70. L. Liaw, M. Almeida, C. E. Hart, S. M. Schwartz, and C. M. Giachelli (1994). Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ. Res. 74:214-224.
71. L. Liaw, V. Lindner, S. M. Schwartz, A. F. Chambers, and C. M. Giachelli (1995). Osteopontin and β3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. Circ. Res. 77:665-672.
72. F. Prols, B. Loser, and M. Marx (1998). Differential expression of osteopontin, PC4, and CEC5, a novel mRNA species, during in vitro angiogenesis. Exp. Cell Res. 239:1-10.
73. M. Scatena, M. Almeida, M. L. Chaisson, N. Fausto, R. F. Nicosia, and C. M. Giachelli (1998). NF-κB mediates αvβ3 integrin-induced endothelial cell survival. J. Cell Biol. 141:1083-1093.
74. U. M. Malyankar, M. Scatena, K. L. Suchland, T. J. Yun, E. A. Clark, and C. M. Giachelli (2000). Osteoprotegerin is an αvβ3-induced, NF-κB-dependent survival factor for endothelial cells. J. Biol. Chem. 275:20959-20962.
75. N. Shijubo, T. Uede, S. Kon, M. Nagata and S. Abe (2000). Vascular endothelial growth factor and osteopontin in tumor biology. Crit. Rev. Oncog. 11:135-146.
76. D. R. Senger, S. R. Ledbetter, K. P. Claffey, A. Papadopoulos-Sergiou, C. A. Peruzzi, and M. Detmar (1996). Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the αvβ3 integrin, osteopontin, and thrombin. Am. J. Pathol. 149:293-305.
77. C. M. Giachelli, D. Lombardi, R. J. Johnson, C. E. Murray, and M. Almeida (1998). Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am. J. Pathol. 152: 53-358.
78. S. Ashkar, G. F. Weber, V. Panoutsakopoulou, M. E. Sanchirico, M. Jansson, S. Zawaideh, S. R. Rittling, D. T. Denhardt, M. J. Glimcher, and H. Cantor (2000). ETA-1 (osteopontin): An early component of type-1 (cell-mediated) immunity. Science 287:860-864.
79. D. T. Denhardt and A. F. Chambers (1994). Overcoming obstacles to metastasis - defences against host defences: Osteopontin (OPN) as a shield against attack by cytotoxic host cells. J. Cell Biochem. 56:48-51.
80. N. S. Fedarko, B. Fohr, P. G. Robey, M. F. Young, and L. W. Fisher (2000). Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J. Biol. Chem. 275:16666-16672.
81. H. C. Crawford, L. M. Matrisian, and L. Liaw (1998). Distinct roles of osteopontin in host defence activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res. 58:5206-5215.
82. H. Nemoto, S. R. Rittling, H. Yoshitake, K. Furuya, T. Amagasa, K. Tsuji, A. Nifuji, D. T. Denhardt, and M. Noda (2001). Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J. Bone Miner. Res. 16:652-659.
83. L. F. Brown, A. Papadopoulos-Sergiou, B. Berse, E. J. Manseau, K. Tognazzi, C. A. Peruzzi, H. F. Dvorak, and D. R. Senger (1994). Osteopontin expression and distribution in human carcinomas. Am. J. Pathol. 145:610-623.
84. A. Bellahcène and V. Castronovo (1995). Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am. J. Pathol. 146:95-100.
85. S. Hirota, A. Ito, J. Nagoshi, M. Takeda, A. Kurata, Y. Takatsuka, K. Kohri, S. Nomura, and Y. Kitamura (1995). Expression of bone matrix protein messenger ribonucleic acids in human breast cancers. Possible involvement of osteopontin in development of calcifying foci. Lab. Invest. 72:64-69.
86. M. T. Gillespie, R. J. Thomas, Z. Y. Pu, H. Zho, T. J. Martin, and D. M. Findlay (1997). Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers. Int. J. Cancer 73:812-815.
87. A. B. Tuck, F. P. O'Malley, H. Singhal, J. F. Harris, K. S. Tonkin, N. Kerkvliet, Z. Saad, G. S. Doig, and A. F. Chambers (1998). Osteopontin expression in a group of lymph node negative breast cancer patients. Int. J. Cancer 79:502-508.
88. J. A. Sharp, V. Sung, J. Slavin, E. W. Thompson, and M. A. Henderson (1999). Tumor cells are the source of osteopontin and bone sialoprotein expression in human breast cancer. Lab. Invest. 79:869-877.
89. A. B. Tuck, F. P. O'Malley, H. Singhal, K. S. Tonkin, J. F. Harris, D. Bautista, and A. F. Chambers (1997). Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch. Pathol. Lab. Med. 121: 78-584.
90. D. S. Bautista, Z. Saad, A. F. Chambers, K. S. Tonkin, F. P. O'Malley, H. Singhal, S. Tokmakejian, V. Bramwell, and J. F. Harris (1996). Quantification of osteopontin in human plasma with an ELISA: Basal levels in pre- and postmenopausal women. Clin. Biochem. 29: 31-239.
91. H. Singhal, D. S. Bautista, K. S. Tonkin, F. P. O'Malley, A. B. Tuck, A. F. Chambers, and J. F. Harris (1997). Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin. Cancer Res. 3:605-611.